CAI On Watch: FDA Clearance, Peer-Reviewed Validation, And Lock-Up Countdown In Focus

AI TechBio company Caris Life Sciences Inc. (CAI) remains active on watchlists following its recent public debut and a series of clinical and regulatory milestones.

The company priced its initial public offering on June 17, 2025, at $21.00 per share, above the initial range, and began trading on the Nasdaq Global Select Market under the ticker "CAI" on June 18, 2025.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com